Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, Mounjaro and Zepbound, after the FDA declares the tirzepatide shortage resolved.
FDA says shortage of popular diabetes, weight-loss drugs resolved
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — has been resolved.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
Eli Lilly’s (NYSE:LLY) blockbuster GLP-1 medication, tirzepatide, is no longer in shortage in the U.S., the U.S. Food and Drug Administration (FDA) said on Wednesday. Tirzepatide, currently marketed by Eli Lilly (LLY) as Mounjaro and Zepbound for diabetes and weight loss,
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
Best Life on MSN15h
Follow These 5 Tips to Lose 30 Pounds Without Ozempic, New Study Says
Glucagon-like peptide-1 (GLP-1) inhibitors like Ozempic, Wegovy, Mounjaro, and Zepbound have helped patients manage their ...
The Scientist1d
The Unexplored Effects of Weight-Loss Drugs on the Brain
Popular weight-loss drugs like Ozempic are used to treat obesity and diabetes. Now, researchers found that these drugs also ...
C&EN9h
Can diabetes drugs like Ozempic tackle the mental health crisis?
Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...
News Medical on MSN3d
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...
The American Journal of Managed Care9h
Legislative Updates, GLP-1s, and More at AMCP Nexus: Adam Colborn
Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.
Pharmaceutical Technology1mon
Glucagon Like Peptide 1 drugs in development, 2024
GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
thorax.bmj10d
Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD
Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...
National Academies of Sciences%2c Engineering%2c and Medicine3mon
Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: A Workshop
to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use ...